finger pointing to an xray scan of brain

Considerations Regarding Non-Inferiority Studies

A case study in multiple sclerosis

May 27, 2021
Michael Murphy, MD, PhD | Tom Babic, MD, PhD | Andrew Kuhlman | William Slone | Jonathan White

While investigational products intended for use in a new formulation are more suited to placebo-controlled study design, biosimilar or “generic” products may be best suited to a non-inferiority (NI) study design, as classical bioequivalence studies are not sufficient in RRMS for the licensing of new generics. This whitepaper discusses seven key considerations for proposing an NI study design. Using relapsing remitting multiple sclerosis (RRMS) as a study case, they outline the non-negotiables, as well as the subtler implications, of these seven elements.

Your form has been successfully submitted! Click the button below to access.
VIEW PDF
Michael Murphy, MD, PhD
MEET THE AUTHOR

Michael Murphy, MD, PhD

Chief Medical and Scientific Officer
LEARN MORE
Tom Babic, MD, PhD
MEET THE AUTHOR

Tom Babic, MD, PhD

Vice President, Scientific Solutions, Neuroscience
LEARN MORE